Cardiol Therapeutics Inc.
Toronto Stock Exchange CRDL.TO
Cardiol Therapeutics Inc. Debt to Equity Ratio for the year ending December 31, 2023
-
Cardiol Therapeutics Inc. Debt to Equity Ratio for the year ending December 31, 2022 was 0.00, a -9.49% change year over year.
-
Cardiol Therapeutics Inc. Debt to Equity Ratio for the year ending December 31, 2021 was 0.00, a -86.93% change year over year.
-
Cardiol Therapeutics Inc. Debt to Equity Ratio for the year ending December 31, 2020 was 0.01, a -9.25% change year over year.
-
Cardiol Therapeutics Inc. Debt to Equity Ratio for the year ending December 31, 2019 was 0.01.
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Don’t Miss A Beat
| CEO | Mr. David G. Elsley MBA |
| IPO Date | Dec. 20, 2018 |
| Location | Canada |
| Headquarters | 2265 Upper Middle Road East |
| Employees | 22 |
| Sector | Healthcare |
| Industries | |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Past 5 years
USD 0.87
StockViz Staff
February 11, 2025
Any question? Send us an email